Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
In summary, available data demonstrate that IL-1 and TNF are the causative agents underlying the bone loss induced by estrogen deficiency. Indeed, these factors are produced in bone and the bone marrow, released in larger amounts from cells of estrogen-deficient subjects, and indispensable for reproducing the effects of estrogen deficiency in bone. These observations support the hypothesis that the bone sparing effect of estrogen is due to the ability of the hormone to block osteoclastogenesis, the activation of mature osteoclasts and, as recently demonstrated, the rate of apoptotic osteoclast death. Although IL-1 and TNF play a prominent causal role in these events, the bone-sparing effect of estrogen is mediated by numerous cytokines which, by simultaneously stimulating multiple target cells, induce effects that are not accounted for by any one single factor (Fig. 2). The ability of estrogen to regulate some, but not all, the cytokines involved in this process is not inconsistent with this hypothesis because cytokines have potent synergistic effects. Thus, a considerable increase in bone resorption may result from a relatively small increase in the concentration of only a few of the bone-resorbing factors present in the bone microenvironment. This concept is best illustrated by the study of Miyaura et al. demonstrating that the concentrations of either IL-1, IL-6, IL-6 receptor, or prostaglandins detected in the bone marrow of OVX mice are insufficient to account for the increased bone resorption caused by estrogen withdrawal. In contrast, the increase in bone resorption induced by OVX can be explained by the cumulative effects of these cytokines. Thus, a better understanding of the cooperative effects of cytokines and a recognition that the contribution of individual cytokines to postmenopausal bone loss varies with the passage of time after menopause are necessary to fully understand the mechanism of action of estrogen in bone. Although the relevance of individual bone-targeting cytokines in species specific, the development of transgenic mice with activatable or deactivatable promoters is likely to result in a further clarification of the integrated action of estrogen-regulated cytokines in human bone cells and lay the foundations for the use of cytokine inhibitors in the treatment of postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen acts via suppression of bone resorption [43–45]”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [44]
In the citing paper
“In addition, estrogen inhibits osteoclast formation by reducing the levels of other osteoclastogenic cytokines such as IL-1, IL-6, IL-11, TNF-α, TNF-β, and M-CSF [160, 161].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [160]
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Modulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004 · cited 2×
“(22) These mice, which are cured by the administration of M-CSF,(3s) have an extra thymidine inserted within the coding region of the M-CSF gene, a mutation that generates a stop codon within the coding sequence,(3h) thereby resulting in the production of a defective M-CSF.(22) The formation of osteoclasts in bone mar…”
BackgroundSoluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Research works printed but not linked: 11
- Srivastava, 1995, Estrogen down-regulates the expression of M-CSF mRNA in bone marrow stromal cells by stimulating the production of the transcription factor EGR-1, J Bone Miner Res, 10, S18
- Matayoshi, 1995, Generation of human osteoclasts from peripheral blood cd 34+ cells, J Bone Miner Res, 10
- Pacifici, 1990, TNFα and GM-CSF secretion from human blood monocytes: Effect of menopause and estrogen replacement, J Bone Miner Res, 5, 145
- Kimble, 1996, Estrogen inhibits IL-1 and TNF gene expression in transfected murine macrophagic cells, J Bone Miner Res, 11
- Kaneki, 1991, The effect of menopause on IL-1 and IL-6 release from peripheral blood monocytes, J Bone Miner Res, 6, 76
- Thompson, 1991, IL-lra: Properties and uses of an interleukin-1 receptor antagonist, Agents Actions, 41
- Girasole, 1995, Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement, and reversed by alendronate administration, J Bone Miner Res, 10, A86
- McKane, 1993, Effect of age and menopause on serum interleukin-1β and intereleukin-6- levels in women, J Bone Miner Res, 8, 162A
- Kimble, 1994, Long-term treatment with IL-1 receptor antagonist (IL-lra) blocks bone loss in ovariectomized rats, J Bone Miner Res, 9, B380
- Kimble, 1995, Inhibition of IL-6 activity is genetically normal mice does not prevent ovariectomy-induced bone loss, J Bone Miner Res, 10, s160
- Ammann, 1995, Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency, J Bone Miner Res, 10
Cited by
Items 201–300 of 743
Nordin, B. E. C., Need, A. G., Morris, H. A., & Horowitz, M. (1999) · Osteoporosis International · doi:10.1007/s001980050158 · Cited by 58
“supportedby reportsof cytokine-mediatedinhibition of boneresorptionby estrogensin vitro [12,13].”
Yamaguchi, T., Kifor, O., Chattopadhyay, N., Bai, M., & Brown, E. M. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.9.1390 · Cited by 63
“Monocytes-macrophages are known to secrete various cytokines, including IL-1, IL-6, and tumor necrosis factor, upon stimulation, such as following the development of estrogen deficiency in the immediate postmenopausal period.((31)) Recently, Ca(21)o was shown to induce the secretion FIG.”
BackgroundPingali, U., & Nutalapati, C. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154334 · Cited by 58
AboElAsrar, M. A., Elbarbary, N. S., ElShennawy, D. E.-S., & Omar, A. M. (2012) · Cytokine · doi:10.1016/j.cyto.2012.03.019 · Cited by 59
“These cytokine induce differentiation of osteoclast precursors into mature osteoclasts, consequently increasing the amount of bone resorption [35] and suppress osteoblast differentiation and bone formation [32].”
BackgroundSponholtz, T. R., Zhang, X., Fontes, J. D., Meigs, J. B., Cupples, L. A., Kiel, D. P., Hannan, M. T., & McLean, R. R. (2013) · Arthritis Care & Research · doi:10.1002/acr.22270 · Cited by 65
“and decreases in BMD (4,6), while menopause hormonal”
BackgroundLei, S., Wu, S., Li, L.-M., Deng, F., Xiao, S., Jiang, C., Chen, Y., Jiang, H., Yang, F., Tan, L., et al. (2008) · Bone · doi:10.1016/j.bone.2008.05.016 · Cited by 59
New treatment targets in osteoporosis
Roux, S. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.02.004 · Cited by 62
Sang, C., Zhang, Y., Chen, F., Huang, P. C., Jin, Q., Wang, P., Zhou, Q., Kang, H., Cao, X., & Guo, L. (2015) · Bone · doi:10.1016/j.bone.2015.12.012 · Cited by 59
Elam, M. L., Johnson, S. A., Hooshmand, S., Feresin, R. G., Payton, M. E., Gu, J. L., & Arjmandi, B. H. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2014.0100 · Cited by 60
“Postmenopausal hormonal deficiency is the most common cause of bone loss and occurs due to an abrupt cessation of estrogen production leading to lower circulating levels of estrogen and subsequently an imbalance between bone resorption and bone formation.(3) Although pharmacologic approaches, for example, bisphosphona…”
González-Calvin, J. L., Mundi, J. L., Casado-Caballero, F. J., Abadia, A. C., & Martin-Ibañez, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0835 · Cited by 53
“There is also evidence that cytokines IL-1 and IL-6 and TNF are elevated after surgical or natural menopause and may be critical factors in postmenopausal osteoporosis (12).”
BackgroundInfluentialFarr, J. N., Khosla, S., Miyabara, Y., Miller, V. M., & Kearns, A. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3406 · Cited by 57
“In addition to altering measurement of vBMD, the red marrow of the spine is rich in immune cells that produce proinflammatory cytokines (eg, IL-1 , IL-6, TNF , granulocyte-monocyte-colony stimulating factor, macrophage colony-stimulating factor, and prostaglandin E2), which support osteoclast differentiation, activity…”
BackgroundOsteoporosis and Bone Health in Transgender Persons
Stevenson, M. O., & Tangpricha, V. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.02.006 · Cited by 56
Gene therapy for osteoporosis: evaluation in a murine ovariectomy model
Baltzer, A. W. A., Whalen, J., Wooley, P. H., Latterman, C., Truchan, L., Robbins, P., & Evans, C. H. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301594 · Cited by 53
Chang, K., Chang, W. H., Yu, Y., & Shih, C. (2004) · Bioelectromagnetics · doi:10.1002/bem.10168 · Cited by 56
Effect of estrogens on IL-1β promoter activity
Ruh, M. F., Bi, Y., DʼAlonzo, R. C., & Bellone, C. J. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00042-9 · Cited by 60
Identification of the Novel Player δEF1 in Estrogen Transcriptional Cascades
Chamberlain, E. M., & Sanders, M. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3600 · Cited by 53
“In fact, estrogen is being implicated in a growing number of human disease states, including reproductive cancers (17), heart disease (2), osteoporosis (20), and Alzheimer’s disease (3).”
BackgroundOestrogen regulates bone resorption and cytokine production in the maxillae of female mice
Macari, S., Duffles, L. F., Queiroz‐Junior, C. M., Madeira, M. F. M., Dias, G. J., Teixeira, M. M., Szawka, R. E., & Silva, T. A. (2014) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2014.11.010 · Cited by 56
Pavlatou, M. G., Remaley, A. T., & Gold, P. W. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.135 · Cited by 56
Fu, S.-W., Zeng, G., Zong, S., Zhang, Z., Zou, B., Ye, F., Lü, L., & Xiao, D.-Q. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.05.003 · Cited by 58
“Estrogen deficiency due to ovarian dysfunction is the dominant cause of osteoporosis in postmenopausal women [3], and studies have established that the postmenopausal decrease in bone mass can be attenuated by estrogen [4, 5].”
BackgroundAssociation between osteoporosis treatment and severe periodontitis in postmenopausal women
Passos‐Soares, J. D. S., Vianna, M. I. P., Gomes‐Filho, I. S., da Cruz, S. S., Barreto, M. L., Adan, L., Rõsing, C. K., Trindade, S. C., Cerqueira, E. M. M., & Scannapieco, F. A. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000830 · Cited by 55
Giampietro, P. F., McCarty, C. A., Mukesh, B. N., McKiernan, F., Wilson, D., Shuldiner, A. R., Liu, J., Levasseur, J. L., Ivacic, L. C., Kitchner, T., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0981-3 · Cited by 56
“Estrogen deficiency results in increased bone loss that may be mediated through the expression of bone cytokines which stimulate bone resorption including IL1, IL6, tumor necrosis factor alpha, and M-CSF, subsequently resulting in increased osteoclast formation and differentiation [ 24 ].”
BackgroundBrooks-Asplund, E. M., Tupper, C. E., Daun, J. M., Kenney, W. L., & Cannon, J. G. (2002) · Cytokine · doi:10.1006/cyto.2002.1963 · Cited by 52
Macrophage migration inhibitory factor‐deficient mice are resistant to ovariectomy‐induced bone loss
Oshima, S., Onodera, S., Amizuka, N., Li, M., Irie, K., Watanabe, S., Koyama, Y., Nishihira, J., Yasuda, K., & Minami, A. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.01.038 · Cited by 50
“There is now a large body of evidence suggesting that estrogen deficiency after natural or surgical menopause increases proinflammatory cytokines such as interleukin (IL)-1, IL-6 , and tumor necrosis factor (TNF)-α [2-5].”
BackgroundNutritional interventions related to bone turnover in European space missions and simulation models
Heer, M. A. (2002) · Nutrition · doi:10.1016/s0899-9007(02)00905-x · Cited by 53
Franchimont, N., Gangji, V., Durant, D., & CANALIS, E. M. (1997) · Endocrinology · doi:10.1210/endo.138.12.5559 · Cited by 50
Deng, F., Liu, Y., Li, L., Chen, J., Wu, S., Chen, Y., Jiang, H., Yang, F., Xiong, J., Xiao, P., et al. (2008) · PROTEOMICS · doi:10.1002/pmic.200700480 · Cited by 50
“Upregulation of osteoclast formation has been recognized as the main mechanism of estrogen deficiency induced bone loss [25, 26].”
Systemic Bone Loss After Fracture
Osipov, B., Emami, A. J., & Christiansen, B. (2018) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-018-9253-0 · Cited by 52
Bertoldo, F., D’Agruma, L., Furlan, F., Colapietro, F., Lorenzi, M. T., Maiorano, N., Iolascon, A., Zelante, L., LoCascio, V., & Gasparini, P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.634 · Cited by 49
Oral Epithelial Overexpression of IL-1α Causes Periodontal Disease
Dayan, S., Stashenko, P., Niederman, R., & Kupper, T. S. (2004) · Journal of Dental Research · doi:10.1177/154405910408301010 · Cited by 54
“IL-1 has also been implicated in the pathogenesis of osteoporosis (Pacifici, 1996).”
BackgroundProtective actions of soy isoflavones and n-3 PUFAs on bone mass in ovariectomized rats
Watkins, B. A., Reinwald, S., Li, Y., & Seifert, M. F. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.019 · Cited by 57
“It seems that COX-2-dependent PG synthesis is necessary for osteoclastogenesis and bone resorption induced by cytokines such as interleukin (IL)1h, tumor necrosis factor-a (TNFa) and lipopolysaccharide (LPS) [31], which are elevated during and aggravate the symptoms of estrogen deficiency on bones [32].”
BackgroundGout and Risk of Fracture in Women: A Prospective Cohort Study
Paik, J. M., Kim, S. C., Feskanich, D., Choi, H. K., Solomon, D. H., & Curhan, G. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39852 · Cited by 50
Association between Postmenopausal Osteoporosis and Experimental Periodontitis
Luo, K., Ma, S., Guo, J., Huang, Y., Yan, F., & Xiao, Y. (2014) · BioMed Research International · doi:10.1155/2014/316134 · Cited by 47
The calcium-sensing receptor in bone
Yamaguchi, T. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0843-7 · Cited by 55
NF-κB and bone: The breaking point
Abu‐Amer, Y., & Tondravi, M. M. (1997) · Nature Medicine · doi:10.1038/nm1197-1189 · Cited by 47
Sialylation of TLR2 initiates osteoclast fusion
Dou, C., Zhen, G., Dan, Y., Wan, M., Limjunyawong, N., & Cao, X. (2022) · Bone Research · doi:10.1038/s41413-022-00186-0 · Cited by 46
“In postmenopausal osteoporosis, preosteoclasts undergo fusion to form osteoclasts much earlier with a relatively short lifespan.(33,34) As a result, osteoclastic bone resorption is increased, whereas blood vessel formation supporting bone formation is decreased, and the net outcome is catabolic bone loss.”
BackgroundGirasole, G., Giuliani, N., Modena, A. B., Passeri, G., & Pedrazzoni, M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00896.x · Cited by 46
“Mounting evidence suggests that bone resorbing cytokines (IL-1, TNF and IL-6), play a central role in the mechanisms by which oestrogen de®ciency causes bone loss (Manolagas & Jilka, 1995; Paci®ci, 1996).”
BackgroundKristo, C., Godang, K., Ueland, T., Lien, E., Aukrust, P., Froland, S., & Bollerslev, J. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460389 · Cited by 45
Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss
Zhang, P., Ye, J., Dai, J., Wang, Y., Chen, G., Hu, J., Hu, Q., & Fei, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.963237 · Cited by 46
“Estrogen can block OC differentiation; Conversely, estrogen withdrawal dramatically promotes OC formation and facilitates bone resorption (36).”
BackgroundPolat, B., Halıcı, Z., Çadırcı, E., Albayrak, A., Karakuş, E., Bayır, Y., Bilen, H., Sahin, A., & Yüksel, T. N. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.07.033 · Cited by 45
Sophocleous, A., Marino, S., Kabir, D., Ralston, S. H., & Idris, A. I. (2017) · Aging Cell · doi:10.1111/acel.12638 · Cited by 46
“Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. 1984; Pacifici, 1996; Raisz, 1996).”
BackgroundLau, H. H. L., Ho, A. Y. Y., Luk, K. D. K., & Kung, A. W. C. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0163-4 · Cited by 46
“TGF-b1 has been implicated as a mediator of the skeletal effects of estrogen [16].”
Effect of Environmental Estrogens on IL-1β Promoter Activity in a Macrophage Cell Line
Ruh, M. F., Bi, Y., Cox, L., Berk, D. R., Howlett, A. C., & Bellone, C. J. (1998) · Endocrine · doi:10.1385/endo:9:2:207 · Cited by 45
Lee, W., Baek, K.-H., Rhee, E., Tae, H.-J., Oh, K.-W., Kang, M. S., Lee, K.-W., Kim, S.-W., Kim, C.-C., & Oh, E. J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704535 · Cited by 50
The Advances in Research on the Pharmacological Effects ofFructus Ligustri Lucidi
Pang, Z., Zhi-yan, Z., Wang, W., Ma, Y., Niu, F., Zhang, X., & Han, C. (2015) · BioMed Research International · doi:10.1155/2015/281873 · Cited by 44
Xiong, H., Peng, B., Wei, L., Zhang, X., & Wang, L. (2007) · Journal of Endodontics · doi:10.1016/j.joen.2007.07.011 · Cited by 44
Gupta, N., Barhanpurkar, A. P., Tomar, G. B., Srivastava, R. K., Kour, S., Pote, S. T., Mishra, G. C., & Wani, M. R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000015 · Cited by 49
“Monocytes obtained from normal females do not give very high bone resorption values as compared with males or post menopausal osteoporotic females because of increased secretion of TNF-a and IL-1 by monocytes of postmenopausal osteoporotic females (27, 29).”
BackgroundExploring the Role of Hormones and Cytokines in Osteoporosis Development
Umur, E., Bulut, S. B., Yiğit, P., Bayrak, E., Arkan, Y., Arslan, F., Baysoy, E., Kaleli‐Can, G., & Ayan, B. (2024) · Biomedicines · doi:10.3390/biomedicines12081830 · Cited by 56
“Preclinical data suggest increased levels of inflammatory mediators and changes in immune cell profiles in rodents with estrogen deficiency [147–150].”
BackgroundThe pathophysiology of osteoporotic hip fracture
Metcalfe, D. (2020) · McGill Journal of Medicine · doi:10.26443/mjm.v11i1.410 · Cited by 56
“It achieves this through the inhibition of a number of cytokines, including IL-1 and TNF, which otherwise activate mature osteoclasts (43).”
BackgroundNasu, M., Sugimoto, T., Kaji, H., & Chihara, K. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1670305 · Cited by 54
“On the other hand, estrogen inhibits bone resorption by directly inhibiting osteoclast activity as well as by decreasing the production of cytokines such as interleukin (IL)-1, tumor necrosis factor (TNF)- and IL-6 from stromal cells (Oursler et al. 1991b, Jilka et al. 1992, Pacifici 1996 ).”
BackgroundGender- and age-related differences in osteoclast formation from circulating precursors
Jevon, M., Sabokbar, A., Fujikawa, Y., HIRAYAMA, T., Neale, S. D., Wass, J. A. H., & Athanasou, N. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720673 · Cited by 46
“interleukin-1 (IL-1), TNF-, IL-6 and M-CSF) which promote osteoclast formation and bone resorption (Manolagas & Jilka 1995, Kimble et al. 1996, Pacifici 1996, Lin et al. 1997, Jilka 1998, Lea et al. 1999).”
BackgroundMusacchio, E., Valvason, C., Botsios, C., Ostuni, F., Furlan, A., Ramonda, R., Modesti, V., Sartori, L., & Punzi, L. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081321 · Cited by 47
Abdelrazek, H. M. A., Mahmoud, M. M. A., Tag, H. M., Greish, S. M., Eltamany, D. A., & Soliman, M. T. A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5713606 · Cited by 48
“Their estrogenic action is attributed to reduction in bone turnover and increased osteoblastic activity [119] of OVX females in order to restore estrogen depletion.”
BackgroundPrevalence of Periapical Lesions in Patients with Osteoporosis
Katz, J., & Rotstein, I. (2020) · Journal of Endodontics · doi:10.1016/j.joen.2020.10.019 · Cited by 42
Ritter, V., Thuering, B., Saint-Mézard, P., Luong-Nguyen, N.-H., Seltenmeyer, Y., JUNKER, U., Fournier, B., Šuša, M., & Morvan, F. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9134-5 · Cited by 43
“The elevated bone loss in postmenopausal OP arises mainly from increased osteoclast formation and bone resorption, attributed to estrogen deficiency in women, although its mechanism of action is still unclear [25].”
BackgroundWang, Z., Wang, L., ZhenYong, W., Jian, W., & Ran, L. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0417-6 · Cited by 42
“In the study, a cytokine that has received considerable attention for bone regulation is TNF-alpha, which is one of the most powerful stimulants of bone resorption known and a well-recognized inhibitor of bone formation [25].”
BackgroundLea, C. K., Sarma, U., & Flanagan, A. M. (1999) · Endocrinology · doi:10.1210/endo.140.1.6451 · Cited by 45
Yoshihiro, W., Horita, T., Ken-ichi, M., Keiichi, O., & Kasugai, S. (1999) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.79.477 · Cited by 41
Sato, T., Watanabe, K., Masuhara, M., Hada, N., & Hakeda, Y. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0723-y · Cited by 41
“the understanding of the pathogenesis and treatment of estrogen deficiency-induced osteoporosis [1–3].”
BackgroundLindberg, M. K., Movérare, S., Eriksson, A.-L., Skrtic, S., Gao, H., Dahlman‐Wright, K., Gustafsson, J.-Α., & Ohlsson, C. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.12.2183 · Cited by 44
“Although up-regulation of osteoclast formation is recognized as the main mechanism by which estrogen deficiency induces bone loss,((4,5)) the responsible cells and cytokines are not completely understood.”
BackgroundDecrease in the number and apoptosis of alveolar bone osteoclasts in estrogen‐treated rats
Faloni, A. P. S., Sasso‐Cerri, E., Katchburian, E., & Cerri, P. S. (2007) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2006.00932.x · Cited by 40
Brennan, O., Kuliwaba, J. S., Lee, T. C., Parkinson, I. H., Fazzalari, N. L., McNamara, L. M., & O’Brien, F. J. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9657-7 · Cited by 45
“appropriate bone turnover in men and women has been well established [23, 24].”
BackgroundZhao, D., Li, X., Zhao, Y., Qiao, P., Tang, D., Chen, Y., Xue, C., Li, C., Liu, S., Wang, J., et al. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.03.007 · Cited by 40
Role of cytokines in postmenopausal bone loss
Pfeilschifter, J. (2003) · Current Osteoporosis Reports · doi:10.1007/s11914-003-0009-4 · Cited by 40
McMillan, J., Kinney, R. C., Ranly, D. M., Fatehi-Sedeh, S., Schwartz, Z., & Boyan, B. D. (2006) · Bone · doi:10.1016/j.bone.2006.07.022 · Cited by 40
“In the absence of estrogen, TNF-α is increased and bone resorption is stimulated [40,41].”
BackgroundRegulation of Collagen Deposition and Lysyl Oxidase by Tumor Necrosis Factor-α in Osteoblasts
Pischon, N., Darbois, L., Palamakumbura, A. H., Kessler, E., & Trackman, P. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404208200 · Cited by 40
Liu, B.-Y. (2002) · Endocrinology · doi:10.1210/en.143.2.627 · Cited by 42
Bashir, A. A., Mak, Y. T., Sankaralingam, S., Cheung, J., Nwa., M., Grigoriadis, A. E., Fogelman, I., & Hampson, G. (2005) · Steroids · doi:10.1016/j.steroids.2005.04.011 · Cited by 43
Notelovitz, M., John, V. A., & Good, W. R. (2002) · Menopause · doi:10.1097/00042192-200209000-00007 · Cited by 39
“(ERT) is effective in preventing postmenopausal osteoporosis.(12,13) Epidemiologic studies demonstrate that”
Backgroundvan Bezooijen, R. L., Farih-Sips, H. C. M., Papapoulos, S. E., & Löwik, C. W. G. M. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.2.185 · Cited by 44
Oral manifestation and its management in postmenopausal women: an integrated review
Sen, S., Sen, S., Dutta, A., Abhinandan, A., Kumar, V., & Singh, A. K. (2020) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2020.97867 · Cited by 39
“Estrogen deficiency leads to upregulation of immune cells (macrophages and monocytes) and osteoclasts, which are responsible for a greater production of bone-resorbing cytokines [28-30].”
BackgroundChenoufi, H., Diamant, M., Rieneck, K., Lund, B., Stein, G. S., & Lian, J. B. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1104 · Cited by 39
“However, while some studies conducted on human osteoblast cell line models have not con®rmed this [Chaudhary et al., 1992; Rifas et al., 1995; Paci®ci, 1996],other ®ndings suggest that age and estrogen status in¯uence either IL6 basal or stimulated levels in bone cells.”
ResultGür, A., Denli, A., Nas, K., Çevik, R., Karakoç, M. A., Saraç, A. J., & Erdoğan, F. (2002) · Rheumatology International · doi:10.1007/s00296-002-0223-x · Cited by 42
“During the past decade, considerable evidence has accumulated suggesting that oestrogen prevents bone loss by blocking the production of proinflammatory cytokines by bone marrow and bone cells [9, 10].”
BackgroundBonnelye, E., & Aubin, J. E. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.8.1392 · Cited by 39
“1392 by Manolagas et al.,(8) Pacifici,(9) and Kong and Penninger(10)).”
Determinants of Osteoporosis Prevention in Low-income Mexican-American Women
Orces, C. H., Casas, C. A., Lee, S., Garcia-Cavazos, R., & White, W. C. (2003) · Southern Medical Journal · doi:10.1097/01.smj.0000051905.38128.b4 · Cited by 42
Bharadwaj, S., Naidu, T. A. G., Betageri, G. V., Prasadarao, N. V., & Naidu, A. S. (2010) · Inflammation Research · doi:10.1007/s00011-010-0211-7 · Cited by 38
“It is well known that pro-inflammatory cytokines IL-6, IL-1b and TNF-a are increased in post-menopausal estrogen deficiency [45–47].”
BackgroundEffects of hormone replacement therapy on immunological factors in the postmenopausal period
Abdi, F., Mobedi, H., Mosaffa, N., Dolatian, M., & Tehrani, F. R. (2016) · Climacteric · doi:10.3109/13697137.2016.1164136 · Cited by 38
Fracture healing: From basic science to role of nutrition
Maria, G. G. (2014) · Frontiers in bioscience · doi:10.2741/4273 · Cited by 41
“The estrogens deficiency after menopause results in an imbalance with a substantial increase in bone turnover, this leading to a progressive loss of trabecular bone, partly due to an increase of osteoclastogenesis (65).”
BackgroundBadger, A. M., Blake, S. M., Dodds, R. A., Griswold, D. E., Swift, B. A., Rieman, D. J., Stroup, G. B., Hoffman, S. J., & Gowen, M. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35249-8 · Cited by 39
“…and prevents bone resorption is by modulating the production of cytokines such as interleukin (IL)-1, tumor necrosis factor-a (TNF-a), and IL-6 (Pacifici, 1996, 1998), and because these cytokines are very likely to be involved in adjuvant disease, this provided additional rationale for testing…”
Fiorelli, G., & Brandi, M. L. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343615 · Cited by 38
Association between antiretrovirals and thyroid diseases: a cross-sectional study
Silva, G. A. R. D., Andrade, M. C. T., Sugui, D. D. A. S., Nunes, R. F., Pinto, J. F. D. C., Silva, W. D. A. E., Ferry, F. R. D. A., Azevedo, M. C. V. M. D., & Motta, R. N. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000023 · Cited by 37
“The mechanism by which HAART causes these changes has not been fully elucidated (3-6).”
BackgroundStructural characterization and osteogenic bioactivities of a novel Humulus lupulus polysaccharide
Chen, X., Li, T., Qing, D., Chen, J., Zhang, Q., & Yan, C. (2019) · Food & Function · doi:10.1039/c9fo01918a · Cited by 37
Tenkumo, T., Aobulikasimu, A., Asou, Y., Shirato, M., Shishido, S., Kanno, T., Niwano, Y., Sasaki, K., & Nakamura, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-65403-4 · Cited by 37
Hepcidin contributes to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss
Guo, H.-H., Xiong, L., Pan, J., Lee, D., Liu, K., Ren, X., Wang, B., Yang, X., Cui, S., Mei, L., et al. (2021) · Bone Research · doi:10.1038/s41413-021-00146-0 · Cited by 39
Type I collagen structure, synthesis, and regulation
Bou–Gharios, G., Abraham, D., & Crombrugghe, B. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00013-0 · Cited by 49
Kettler, D. B. (2001) · PubMed · Cited by 48
Caspase-Dependent Cleavage of Cadherins and Catenins During Osteoblast Apoptosis
Hunter, I., Mcgregor, D., & Robins, S. P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.466 · Cited by 44
“(TNF-a) and interleukin-1 (IL-1), present in the bone microenvironment and recognized as powerful stimulants of bone resorption and inhibitors of bone formation, (60) recently have been shown to down-regulate the expression of N-cadherin in the mouse osteoblastic cell line MC3T3E1.”
BackgroundErlandsson, M. C., Islander, U., Movérare, S., Ohlsson, C., & Carlsten, H. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_113502.x · Cited by 37
“Bone resorption following estrogen deficiency is primarily caused by increased numbers of bone-resorbing osteoclasts (20), which previously were believed to develop exclusively from stem cells of myelopoietic lineage.”
BackgroundBoyce, B. F., Hughes, D. E., Wright, K. R., Xing, L., & Dai, A. (1998) · Springer eBooks · doi:10.1007/978-3-662-09007-7_3 · Cited by 38
Ng, K. W., Romas, E., Donnan, L. T., & Findlay, D. M. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80473-9 · Cited by 38
Millet, I., McCarthy, T. L., & Vignery, A. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1092 · Cited by 37
Fornusek, C. P., & Kilbreath, S. L. (2017) · Journal of Cancer Survivorship · doi:10.1007/s11764-017-0622-3 · Cited by 36
Shozu, M., Zhao, Y., & R. Simpson, E. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00233-6 · Cited by 36
Fülöp, B., Hunyady, Á., Bencze, N., Kormos, V., Szentes, N., Dénes, Á., Lénárt, N., Borbély, É., & Helyes, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065479 · Cited by 39
“The loss of estrogen in postmenopausal women results in elevated cytokine levels, including IL-1, which is involved in osteoporosis [69].”
BackgroundBone Mineral Density and Risk of Heart Failure in Older Adults: The Cardiovascular Health Study
Fohtung, R. B., Brown, D., Koh, W. J. H., Bartz, T. M., Carbone, L. D., Civitelli, R., Stein, P. K., Chaves, P. H. M., Kestenbaum, B. R., & Kizer, J. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004344 · Cited by 40
“It could relate to the fact that the prevalence of osteoporosis in women is higher than in men and fostered by the postmenopausal state.(38) In this regard, the lack of association could pertain to menopause being such a dominant risk factor for osteoporosis that—given that all”
BackgroundBernard-Poenaru, O., Roux, C., Blanqué, R., Gardner, C. R., de Vernejoul, M. C., & Cohen-Solal, M. E. (2001) · Osteoporosis International · doi:10.1007/s001980170054 · Cited by 36
“PBMC have been peformed on adherent monocytes, some showing decreased levels after in vivo treatment and others showing no changes [2].”
BackgroundAl‐Obaidi, M. M. J., Al-Bayaty, F. H., Batran, R. A., Hassandarvish, P., & Rouhollahi, E. (2014) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2014.06.001 · Cited by 38
VURAL, P., Canbaz, M., & Akgül, C. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.01.005 · Cited by 40
Contribution of membrane‐associated prostaglandin E2 synthase to bone resorption
Saegusa, M., Murakami, M., Nakatani, Y., Yamakawa, K., Katagiri, M., Matsuda, K., Nakamura, K., Kudo, I., & Kawaguchi, H. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10356 · Cited by 41
“We and others have reported that upregulation of IL-1 and TNF-aproduction in bone marrow are implicated in bone loss with estrogen withdrawal at least partly through PGE2 production (Kawaguchi et al., 1995c; Pacifici, 1996; Pfeilschifter et al., 2002).”
BackgroundValladares, A., Porrás, A., Alvarez, A. M., Roncero, C., & Benito, M. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200012)185:3<408::aid-jcp11>3.0.co;2-2 · Cited by 26
Wang, F.-S., Wang, C.-J., Chen, Y.-J., Huang, Y.-T., Huang, H.-C., Chang, P.-R., Sun, Y.-C., & Yang, K. D. (2004) · Endocrinology · doi:10.1210/en.2003-1074 · Cited by 35
“Estrogen deficiency, a major risk factor for osteoporosis, is characterized by high bone turnover with enhanced osteoclastic bone resorption (1, 2).”
Background
Metadata
- Authors
- Pacifici, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Pacifici, Roberto
- ORCID
- Pacifici, Roberto
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2110993073
- Cited by
- 741
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 20 · 2021: 24 · 2020: 20 · 2019: 26 · 2018: 30 · 2017: 15 · 2016: 19 · 2015: 31 · 2014: 29 · 2013: 22 · 2012: 28
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag013534-04)
- National Institute on Aging (AG 13534)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041412, AR41412)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- postmenopausal osteoporosis, estrogen deficiency, cytokines, interleukin-1, TNF-α, bone resorption, osteoclastogenesis, osteoclast apoptosis, bone marrow, cytokine synergy, estrogen withdrawal, cytokine inhibitors
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Estrogens, Female, Humans, Menopause, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.